Dosage of enoxaparin among obese and renal impairment patients
- 1 January 2005
- journal article
- clinical trial
- Published by Elsevier in Thrombosis Research
- Vol. 116 (1) , 41-50
- https://doi.org/10.1016/j.thromres.2004.10.004
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Effect of Renal Function on the Pharmacokinetics of Enoxaparin and Consequences on Dose AdjustmentTherapeutic Drug Monitoring, 2004
- Is Impaired Renal Function a Contraindication to the Use of Low-Molecular-Weight Heparin?Archives of internal medicine (1960), 2002
- Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromesAmerican Heart Journal, 2002
- Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairmentThrombosis Research, 2002
- Enoxaparin in unstable angina patients with renal failureInternational Journal of Cardiology, 2001
- The Pharmacokinetics of Subcutaneous Enoxaparin in End‐Stage Renal DiseasePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2001
- Dosing and Monitoring of Low‐Molecular‐Weight Heparins in Special PopulationsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2001
- Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and SafetyChest, 2001
- Aging and Venous Thromboembolism Influence the Pharmacodynamics of the Anti-Factor Xa and Anti-thrombin Activities of a Low Molecular Weight Heparin (Nadroparin)Thrombosis and Haemostasis, 1998
- Low-Molecular-Weight HeparinsNew England Journal of Medicine, 1997